Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Every Certificate of Analysis we've ingested from retaonelabs.com, what each tests for, and what's missing. Sourced back to the original COA URLs — no hosting, no editorial.
Issues our data pipeline flagged on this vendor's COAs. Each flag points at a specific COA and the reason it was raised.
COA labeled 10.00mg but archived vendor listing (mots-c-40mg @ 2026-05-28) shows 40.00mg — 300% drift
Each row is one peptide. Columns show whether at least one COA from this vendor for that peptide tests for that property. Endotoxin and sterility are usually the gap.
| Peptide | COAs | Avg purity | HPLC | MS/MALDI | NMR | Endotoxin | Sterility | Metals | Microbial |
|---|---|---|---|---|---|---|---|---|---|
| Bacteriostatic Water | 1 | — | — | — | — | — | — |
Most recent batches we've ingested. Each row links to the original COA file as published by the vendor.
| Peptide | Lot | Lab | Purity | Tests | Tested | |
|---|---|---|---|---|---|---|
| MOTS-c | MTS100626 | Kovera Labs | 99.24% | LALUSP<71>HM | — | View |
| BPC-157/TB-500 | — | Kovera Labs | 99.65% | MSLALUSP<71>HM | — | View |
How this is built: we discover every COA URL on the vendor's public testing page, fetch the file, run structured extraction, and persist what each COA actually tests for. Vendor copy isn't a signal — only the COAs themselves.
Full methodology →| BPC-157 | 1 | 99.36% | — | — | — |
| BPC-157/TB-500 | 1 | 99.65% | — | — |
| CJC-1295 (No DAC)/Ipamorelin | 1 | 99.77% | — | — |
| GHK-Cu | 4 | 99.78% | — |
| Glow | 1 | 99.76% | — | — |
| Klow | 2 | 99.45% | — |
| MOTS-c | 3 | 99.68% | — |
| NAD+ | 2 | 99.44% | — |
| PT-141 | 1 | 99.86% | — |
| Retatrutide | 12 | 99.72% | — |
| Semaglutide | 2 | 99.53% | — | — | — | — |
| SS-31 | 1 | 99.19% | — |
| Tesamorelin | 4 | 99.58% | — |
| Tesofensine | 2 | — | — | — | — | — | — | — |
| Tirzepatide | 7 | 99.89% | — |
| Tirzepatide | TZ600326 | Kovera Labs | 99.90% | MSLALUSP<71>HM | — | View |
| Klow | KL800526 | Kovera Labs | 99.91% | MSLALUSP<71>HM | — | View |
| Tirzepatide | TZ300326 | Kovera Labs | 99.92% | MSLALUSP<71>HM | — | View |
| Tesamorelin | TS100326 | Kovera Labs | 99.92% | MSLALUSP<71>HM | — | View |
| Tesamorelin | TS200526 | Kovera Labs | 99.89% | MSLALUSP<71>HM | — | View |
| KLOW | KL801025 | Vanguard Laboratory | 99.00% | — | — | View |
| Retatrutide | RT500326 | Kovera Labs | 99.89% | MSLALUSP<71>HM | — | View |
| — | — | — | — | — | — | View |
| GHK-Cu | GK1000426 | Kovera Labs | 99.86% | MSLALUSP<71>HM | — | View |
| NAD+ | NAD112025 | Vanguard Laboratory | 99.00% | — | — | View |
| SS-31 | SS100626 | Kovera Labs | 99.19% | MSLALUSP<71>HM | — | View |
| Retatrutide | R401125 | Vanguard Laboratory | 99.80% | — | — | View |
| Tirzepatide | TZ100326 | Kovera Labs | 99.88% | MSLALUSP<71>HM | — | View |
| MOTS-c | MTS100326 | Kovera Labs | 99.86% | MSLALUSP<71>HM | — | View |
| — | — | — | — | — | — | View |
| CJC-1295 (No DAC)/Ipamorelin | CJIP0326 | Kovera Labs | 99.77% | MSLALUSP<71>HM | — | View |
| Tesamorelin | TS100526 | Kovera Labs | 99.18% | MSLALUSP<71>HM | — | View |
| Retatrutide | R601025 | Vanguard Laboratory | — | LALUSP<71> | — | View |
| Retatrutide | RT100326 | Kovera Labs | 99.81% | MSLALUSP<71>HM | — | View |
| Retatrutide | RT600326 | Kovera Labs | 99.88% | MSLALUSP<71>HM | — | View |
| Retatrutide | RT200326 | Kovera Labs | 99.83% | MSLALUSP<71>HM | — | View |
| Glow | — | Kovera Labs | 99.76% | MSLALUSP<71>HM | — | View |
| PT-141 | PT100526 | Kovera Labs | 99.86% | MSLALUSP<71>HM | — | View |
| Retatrutide | RT300326 | Kovera Labs | 99.86% | MSLALUSP<71>HM | — | View |
| NAD+ | NAD5000526 | Kovera Labs | 99.89% | MSLALUSP<71>HM | — | View |
| Tirzepatide | TR300626 | Kovera Labs | 99.96% | MSLALUSP<71>HM | — | View |
| MOTS-c | MTS400526 | Kovera Labs | 99.95% | MSLALUSP<71>HM | — | View |
| Bacteriostatic Water | BW78916 | Kovera Labs | — | LAL | 2026-05-28 | View |
| Semaglutide | SM100326 | Vanguard Laboratory | 99.76% | — | 2026-02-23 | View |
| Semaglutide | SM200326 | Vanguard Laboratory | 99.31% | — | 2026-02-23 | View |
| Retatrutide | R61025 | Vanguard Laboratory | 99.48% | — | 2025-12-16 | View |
| GHK-Cu Serum | — | Vanguard Laboratory | — | — | 2025-12-01 | View |
| GHK-Cu Serum | — | Vanguard Laboratory | — | — | 2025-12-01 | View |
| Tesamorelin | TS101125 | Vanguard Laboratory | 99.34% | — | 2025-10-22 | View |
| Tesofensine | TES5000925 | Vanguard Laboratory | — | — | 2025-10-10 | View |
| Tesofensine | TES500925 | Vanguard Laboratory | — | — | 2025-10-10 | View |
| Tirzepatide | TR300925 | Vanguard Laboratory | 99.80% | — | 2025-10-03 | View |
| Tirzepatide | TR301025 | Vanguard Laboratory | 99.88% | — | 2025-10-03 | View |
| GHK-Cu | GK500925 | Chromate | 99.71% | LAL | 2025-09-24 | View |
| BPC-157 | Bp100925 | Chromate | 99.36% | LALUSP<71> | 2025-09-24 | View |
| Tirzepatide | TR600925 | Chromate | 99.87% | LAL | 2025-09-24 | View |
| Retatrutide | R20725 | Chromate | 99.50% | LALUSP<71>HM | 2025-09-09 | View |
| Retatrutide | R30725 | Chromate | 99.75% | LALUSP<71>HM | 2025-09-09 | View |
| Retatrutide | R10725 | Chromate | 99.30% | LALUSP<71> | 2025-09-08 | View |
| Retatrutide | R50725 | Chromate | 99.84% | — | 2025-08-18 | View |
Disclosed Labs